We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01606995
Recruitment Status : Completed
First Posted : May 28, 2012
Last Update Posted : August 3, 2022
Sponsor:
Collaborator:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Bayer

Brief Summary:
This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.

Condition or disease Intervention/treatment
Atrial Fibrillation Drug: Rivaroxaban (Xarelto, BAY59-7939)

Layout table for study information
Study Type : Observational
Actual Enrollment : 6784 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation
Actual Study Start Date : June 12, 2012
Actual Primary Completion Date : March 6, 2015
Actual Study Completion Date : March 31, 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Rivaroxaban

Group/Cohort Intervention/treatment
Group 1 Drug: Rivaroxaban (Xarelto, BAY59-7939)
Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator




Primary Outcome Measures :
  1. Adjudicated major bleeding events [ Time Frame: after 1 year or until 30 days after end of rivaroxaban therapy ]
  2. Safety variables will be summarized using descriptive statistics based on adverse events collection [ Time Frame: after 1 year or until 30 days after end of rivaroxaban therapy ]

Secondary Outcome Measures :
  1. All cause mortality [ Time Frame: after 1 year or until 30 days after end of rivaroxaban therapy ]
  2. Adjudicated symptomatic thromboembolic events [ Time Frame: after 1 year or until 30 days after end of rivaroxaban therapy ]
  3. Persistence with rivaroxaban treatment: Reasons for any switch from or interruption of rivaroxaban treatment [ Time Frame: after 1 year or until 30 days after end of rivaroxaban therapy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism
Criteria

Inclusion Criteria:

  • Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01606995


Locations
Layout table for location information
Austria
Multiple Locations, Austria
Belgium
Multiple Locations, Belgium
Canada
Multiple Locations, Canada
Czechia
Multiple Locations, Czechia
Denmark
Multiple Locations, Denmark
France
Multiple Locations, France
Germany
Multiple Locations, Germany
Hungary
Multiple Locations, Hungary
Ireland
Multiple Locations, Ireland
Israel
Multiple Locations, Israel
Moldova, Republic of
Multiple Locations, Moldova, Republic of
Netherlands
Multiple Locations, Netherlands
Norway
Multiple Locations, Norway
Poland
Multiple Locations, Poland
Portugal
Multiple Locations, Portugal
Russian Federation
Multiple Locations, Russian Federation
Slovakia
Multiple Locations, Slovakia
Slovenia
Multiple Locations, Slovenia
Sweden
Multiple Locations, Sweden
Ukraine
Multiple Locations, Ukraine
United Kingdom
Multiple Locations, United Kingdom
Sponsors and Collaborators
Bayer
Janssen Research & Development, LLC
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01606995    
Other Study ID Numbers: 15914
XA1101 ( Other Identifier: Company internal )
First Posted: May 28, 2012    Key Record Dates
Last Update Posted: August 3, 2022
Last Verified: July 2022
Keywords provided by Bayer:
Stroke
Embolism
Atrial fibrillation
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Cardiovascular Diseases
Arrhythmias, Cardiac
Heart Diseases
Pathologic Processes
Rivaroxaban
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants